Chan Mitchell — SEC insider filings
SEC reporting owner CIK 1789335. 15 insider filings on record with FilingPulse; latest filed 2026-11-03.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2021-03-15 to 2026-11-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 3,167 shares, $72,461 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 3,167 shares @ $22.88 ($72,461) in Avalo Therapeutics, Inc., filed 2026-05-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | Director | 8 | — | 1 leg · 3,167 sh · $72,461 | 10 |
| REGENXBIO Inc. (RGNX) | Chief Financial Officer | 6 | — | — | 8 |
| Viela Bio, Inc. (VIE) | Chief Financial Officer | 1 | — | — | 5 |
Insider filings — Chan Mitchell
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 4 | REGENXBIO Inc. (RGNX) | Grant/award (A): 24,305 @ $0 | EDGAR |
| 2026-09-03 | 4 | REGENXBIO Inc. (RGNX) | Tax withholding (F): 4,902 @ $9.32 | EDGAR |
| 2026-05-07 | 4 | Avalo Therapeutics, Inc. (AVTX) | Sale (S): 3,167 @ $22.88 | EDGAR |
| 2026-03-31 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 3,166 · Option exercise (M): 3,166 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | REGENXBIO Inc. (RGNX) | Grant/award (A): 73,749 @ $0 · Grant/award (A): 39,650 (derivative) @ $0 | EDGAR |
| 2025-09-03 | 4 | REGENXBIO Inc. (RGNX) | Tax withholding (F): 4,901 @ $8.93 | EDGAR |
| 2025-06-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 3,167 · Option exercise (M): 3,167 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | REGENXBIO Inc. (RGNX) | Grant/award (A): 62,547 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | REGENXBIO Inc. (RGNX) | Grant/award (A): 58,869 @ $0 · Grant/award (A): 289,362 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 24,600 (derivative) @ $0 · Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2023-12-21 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 3,334 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-03-15 | 4 | Viela Bio, Inc. (VIE) | Disposition to issuer (D): 37,500 @ $53 · Disposition to issuer (D): 50,056 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 67,500 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-08 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1789335 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs